Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiome Effects in Telitacicept-Treated Systemic Lupus Erythematosus Patients
ChiCTR2200064438Phase 4Not yet recruiting
- Sponsor
- Xuzhou No. 1 People's Hospital
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of telitacicept in systemic lupus erythematosus (SLE) (2 arms), sponsored by Xuzhou No. 1 People's Hospital. Primary endpoints: Laboratory data, Fecal IgA level and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2200064438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064438.